Clinical Trial

Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 6, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients with hereditary hemorrhagic telangiectasia (HHT) suffer from an inherited disorder leading to systemic vascular malformations. Mutations in several genes of the transforming growth factor (TGF)-β superfamily pathway influence angiogenesis in patients with HHT. The genetic loss of ALK1 or ENG alone are not sufficient to induce AVMs; environmental insults that could trigger angiogenesis (e.g. wounding) are also needed. In this study it will be analyzed if hypoxic induced factors could have an influence on the disease HHT.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-07-08; most recent amendment 2024-12-05.
Status change: Not Yet Recruiting → Recruiting 2020-11-02
Trial Details
NCT Number NCT04469517
Lead Sponsor University Hospital, Essen
Conditions Hereditary Hemorrhagic Telangiectasia
Enrollment 100 participants
Start Date 2020-08-10
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-06